https://ph-ksp.com/liquidia-lqda-presents-new-yutrepia-data-at-the-us-pulmonary-hypertension-association-phas-international-annual-conference-in-dallas-june-11-14-2026/ 2026-06-24T19:34:44Z PULMONARY HYPERTENSION en Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026 2026-06-24T13:56:01Z Blog https://ph-ksp.com/an-roundtable-of-us-pulmonologists-discusses-sotatercept-de-escalation-and-the-limits-of-upfront-therapy-for-pulmonary-arterial-hypertension-hcp-live-june-22-2026/ 2026-06-24T10:23:20Z PULMONARY HYPERTENSION en A roundtable of US pulmonologists discusses sotatercept, de-escalation, and the limits of upfront therapy for pulmonary arterial hypertension, HCP Live, June 22, 2026 2026-06-24T10:16:28Z Blog https://ph-ksp.com/exploring-the-therapeutic-potential-of-glp-1-receptor-agonists-in-pulmonary-arterial-hypertension-european-respiratory-journal-may-2026/ 2026-06-24T05:18:50Z PULMONARY HYPERTENSION en Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension, European Respiratory Journal, May 2026 2026-06-24T05:18:48Z Blog https://ph-ksp.com/corsair-pharma-announces-three-presentations-of-phase-1-clinical-data-for-trx-248-transdermal-system-at-the-2026-pulmonary-hypertension-association-conference/ 2026-06-24T04:59:33Z PULMONARY HYPERTENSION en Corsair Pharma Announces Three Presentations of Phase 1 Clinical Data for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference 2026-06-24T04:59:31Z Blog https://ph-ksp.com/regeneron-pharmaceuticals-expands-into-pulmonary-arterial-hypertension-with-phase-2-trial-for-regn13335/ 2026-06-24T04:48:23Z PULMONARY HYPERTENSION en Regeneron Pharmaceuticals expands Into pulmonary arterial hypertension with Phase 2 trial for REGN13335 2026-06-24T04:48:11Z Blog https://ph-ksp.com/upfront-triple-combination-therapy-with-selexipag-insights-from-a-real-world-cohort-in-chinese-patients-with-pulmonary-arterial-hypertension-frontiers-in-cardiovascular-medicine-may-21-2026/ 2026-06-23T06:03:17Z PULMONARY HYPERTENSION en Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026 2026-06-23T06:03:16Z Blog